The benefits of angiotensin II receptor blockers in patients with renal insufficiency or failure

American Journal of Therapeutics

Volumn 5, Issue 2, 1998, Pages 101-105

  Ram, C Venkata S ^a   Fierro, Gustavo ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Angiotensin receptor blocker; Hypertension; Losartan; Renal disease

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; CHOLESTEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LOSARTAN; LOW DENSITY LIPOPROTEIN; RENIN; VERY LOW DENSITY LIPOPROTEIN;

CLINICAL TRIAL; COUGHING; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; GLOMERULOSCLEROSIS; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; HYPERURICOSURIA; KIDNEY FAILURE; NONHUMAN; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SODIUM TRANSPORT;

EID: 0031901712     PISSN: 10752765     EISSN: None     Source Type: Journal    
DOI: 10.1097/00045391-199803000-00008     Document Type: Review

References (21)

1. Klag MJ, Whelton PK, Randall BL, et al: Blood pressure and end-stage renal disease in men. N Engl J Med 1996; 334:13-18.
2. Xie M-H, Liu F-Y, Wong PC, et al: Proximal nephron and renal effects of DuP 753, a nonpeptide angiotensin II receptor antagonist. Kidney Int 1990;38:473-479.
3. Huckle WR, Earp HS: Regulation of cell proliferation and growth by angiotensin II. Prog Growth Factor Res 1994;5:177-194.
4. Tufro-McReddie A, Romano LM, Harris JM, et al: Angiotensin II regulates nephrogenesis and renal vascular development. Am J Physiol 1995;269:F110-F115.
5. Orth SR, Weinreich T, Bönisch S, et al: Angiotensin II induces hypertrophy and hyperplasia in adult human mesangial cells. Exp Nephrol 1995;3:23-33.
6. Anderson S, Brenner BM: The role of nephron mass and of intraglomerular pressure in initiation and progression of experimental hypertensive-renal disorders. In: Hypertension: Pathophysiology, Diagnosis and Management, 2nd ed. (Eds. Laragh JH, Brenner BM), Raven Press, New York, 1995, pp. 1553-1568.
7. Lafayette RA, Mayer G, Park SK, et al: Angiotensin II receptor blockade limits glomerular injury in rats with reduced renal mass. J Clin Invest 1992;90:766-771.
8. Pollock DM, Divish BJ, Polakowski JS, et al: Angiotensin II receptor blockade improves renal function in rats with reduced renal mass. J Pharmacol Exp Ther 1993;267:657-663.
9. Mayer G, Lafayette RA, Oliver J, et al: Effects of angiotensin II receptor blockade on remnant glomerular permselectivity. Kidney Int 1993;43:346-353.
10. Kohzuki M, Kanazawa M, Liu PF, et al: Kinin and angiotensin II receptor antagonists in rats with chronic renal failure: chronic effects on cardio- and renoprotection of angiotensin converting enzyme inhibitors. J Hypertens 1995;13:1785-1790.
11. Gansevoort RT, de Zeeuw D, Shahinfar S, et al: Effects of the angiotensin II antagonist losartan in hypertensive patients with renal disease. J Hypertens 1994;12(Suppl 2):S37-S42.
12. Shaw W, Keane W, Sica D, et al: Safety and antihypertensive effects of losartan (MK-954; DuP 753), a new angiotensin II receptor antagonist, in patients with hypertension and renal disease. Clin Pharmacol Ther [Abstract PI-19] 1993;53:140.
13. Shaw W, Snavely D, Shahinfar S: Safety and efficacy of losartan (DuP 753, MK-954) in hypertensive patients with renal impairment. J Am Soc Nephrol [Abstract] 1994;5:567.
14. de Zeeuw D, Gansevoort RT, Dullaart RPF, et al: Angiotensin II antagonism improves the lipoprotein profile in patients with nephrotic syndrome. J Hypertens 1995;13(Suppl 1):S53-S58.
15. Weidmann P, Uehlinger DE, Gerber A: Antihypertensive treatment and serum lipoproteins. J Hypertens [Editorial Review] 1985;3:297-306.
16. Burnier M, Waeber B, Brunner HR: The advantages of angiotensin II antagonism. J Hypertens 1994;12(Suppl 2):S7-S15.
17. Lacourcière Y, Brunner H, Irwin R, et al: Effects of modulators of the renin-angiotensin-aldosterone system on cough. J Hypertens 1994;12:1387-1393.
18. Vane J: Trumping the ACE. Lancet [Letter] 1995;346:916.
19. Azizi M, Chatellier G, Guyene T-T, et al: Additive effects of combined angiotensin-converting enzyme inhibition and angiotensin II antagonism on blood pressure and renin release in sodium-depleted normotensives. Circulation 1995;92:825-834.
20. Lo M-W, Goldberg MR, McCrea JB, et al: Pharmacokinetics of losartan, an angiotensin II receptor antagonist, and its active metabolite EXP 3174 in humans. Clin Pharmacol Ther 1995;58:641-649.
21. Sica DA, Lo M-W, Shaw WC, et al: The pharmacokinetics of losartan in renal insufficiency. J Hypertens 1995;13(Suppl 1):S49-S52.